In vitro and in vivo effect of IFNα on B16F10 melanoma in two models: Subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice)

Conesa, Cristina Martínez; Álvarez-Sánchez, Nuria; Ortega, Vicente Vicente; Reverte, Juana García; Carpe, Fernando Pascual; Aranda, M. Campos

doi:10.1016/j.biopha.2008.07.092

Cited by 8 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results appear to be in contradiction with those published by Martínez et al [6] where IFN-alpha showed decreased cell survival in a time and dose-dependent manner when used in B16F10 cells, but Migration assay 5×10 3 B16F10 cells were seeded in the upper compartment of transwell cell culture chambers (Falcon Cell Culture Inserts, Becton-Dickinson Laboratories, Orangeburg, NY, USA) in 24-well microplates and cultured in 1% FCS medium with 1000 IU/mL of MF ( Figure 2). After 48 hours, melanoma cells migrated to the filter (8 μm diameter pores) and adhered to the lower surface of the 24-well microplate.…”

Section: Journal Of Clinical and Experimental Dermatology Researchcontrasting

confidence: 99%

“…the doses of MF used by this authors (250000-1000000 IU/mL) were much higher than the doses we used in our work (0-1000 IU/mL), and this difference of concentration could explain the lack of antitumoral activity of MF in our in vitro study. According to the pharmacokinetic data available on recombinant IFN-alpha [4], we believe that the concentrations of MF that we have used in our experiments (0-1000 IU/ mL) are comparable to the real concentration of MF in the intercellular space in patients receiving treatment with this drug, whereas the concentrations previously used in other in vitro experimental studies (20000-1000000 IU/mL) [6,7] seem too high.…”

Section: Discussionmentioning

confidence: 59%

See 1 more Smart Citation

Antitumoral Activity of Multiferon® (HulFN-alpha-Le) in Experimental Murine Melanoma Model

Blaya¹

2013

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Multiferon® (HuIFN-alpha-Le) (MF) is a natural interferon alpha used in several countries for the treatment of selected viral infections and as an adjuvant treatment in different types of cancer, including melanoma. We have examined the influence of MF in vitro and in vivo in murine melanoma cells. B16F10 cells were treated with MF at different concentrations ranging from 0 to 1000 IU/mL and this substance had no effect on cell proliferation, migration or clonogenic abilities of the tumoral cells. However, in vivo studies with murine models after subcutaneous implantation of B16F10 cells showed that tumor volumes measured during the experiment and at sacrifice were significantly smaller in mice receiving MF (90 IU/mice 3 times a week) than in the control group (p<0.005). MF was well tolerated and no body weight loss or other sign of toxicity was observed in all groups. These results indicate that MF is active in vivo in murine experimental melanoma model without showing any direct antimelanoma activity in in vitro assays when used at doses mimicking the serum levels found in clinical practice in humans. We believe that the activation of the immune system following the administration of MF may be one of the mechanisms that explain the anti-tumoral effect of this drug.

show abstract

Section: Journal Of Clinical and Experimental Dermatology Researchcontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 59%

Antitumoral Activity of Multiferon® (HulFN-alpha-Le) in Experimental Murine Melanoma Model

Blaya¹

2013

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

show abstract

“…In more recent studies, B16-F10 tumor-bearing mice with pulmonary metastases were used to screen potential antimelanoma molecules and evaluate their antimetastatic activity, including a specific inhibitor of thrombin, recombinant hirudin with stealthy liposomal vinblastine (98), a heterodimer recombinant (r) IL-7/HGFb that was cloned and expressed as a single-chain hybrid cytokine (95), nanoencapsulated alkanoid Camptothecin (CPT) (99), interferon alpha (100), an aqueous extract from the root of Platycodon grandiflorum (96), berberine (101), and RAM, an RGD-non-peptide Analog-Molecule that markedly reduced up to 80% of lung metastases development (102). In addition, the antimetastatic activity of the theophylline analog 7-(2-hydroxyethyl)theophylline (HET) (103), peptides corresponding to conserved complementary determining regions from different immunoglobulins (104), carbamoylphosphonates (CPOs) (105), and C4-benzazole naphthalimide derivatives (106) were also screened using this model.…”

Section: Introductionmentioning

confidence: 99%

The Melding of Drug Screening Platforms for Melanoma

et al. 2019

View full text Add to dashboard Cite

The global incidence of cancer is rising rapidly and continues to be one of the leading causes of death in the world. Melanoma deserves special attention since it represents one of the fastest growing types of cancer, with advanced metastatic forms presenting high mortality rates due to the development of drug resistance. The aim of this review is to evaluate how the screening of drugs and compounds for melanoma has been performed over the last seven decades. Thus, we performed literature searches to identify melanoma drug screening methods commonly used by research groups during this timeframe. In vitro and in vivo tests are essential for the development of new drugs; however, incorporation of in silico analyses increases the possibility of finding more suitable candidates for subsequent tests. In silico techniques, such as molecular docking, represent an important and necessary first step in the screening process. However, these techniques have not been widely used by research groups to date. Our research has shown that the vast majority of research groups still perform in vitro and in vivo tests, with emphasis on the use of in vitro enzymatic tests on melanoma cell lines such as SKMEL and in vivo tests using the B16 mouse model. We believe that the union of these three approaches ( in silico, in vitro , and in vivo ) is essential for improving the discovery and development of new molecules with potential antimelanoma action. This workflow would provide greater confidence and safety for preclinical trials, which will translate to more successful clinical trials and improve the translatability of new melanoma treatments into clinical practice while minimizing the unnecessary use of laboratory animals under the principles of the 3R's.

show abstract

“…O pulmão é o órgão mais comumente atacado pela disseminação metastática do melanoma cutâneo (18-36%). O arsenal terapêutico disponível para o tratamento da doença em estágio avançado traz resultados insatisfatórios, logo, estudos in vitro e in vivo são de fundamentais importância para o melhor conhecimento do comportamento biológico dessa neoplasia e para o desenvolvimento diagnóstico e terapêutico (Silva et al, 2013;Conesa et al, 2008).…”

Section: Embora a Medicina Moderna Seja Bastante Desenvolvida A Orgaunclassified

Avaliação dos efeitos antineoplásicos in vitro e in vivo do látex da Euphorbia tirucalli (aveloz) no melanoma murino B16/F10

Brunetti¹

View full text Add to dashboard Cite

show abstract

In vitro and in vivo effect of IFNα on B16F10 melanoma in two models: Subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice)

Cited by 8 publications

References 26 publications

Antitumoral Activity of Multiferon® (HulFN-alpha-Le) in Experimental Murine Melanoma Model

Antitumoral Activity of Multiferon® (HulFN-alpha-Le) in Experimental Murine Melanoma Model

The Melding of Drug Screening Platforms for Melanoma

Avaliação dos efeitos antineoplásicos in vitro e in vivo do látex da Euphorbia tirucalli (aveloz) no melanoma murino B16/F10

Contact Info

Product

Resources

About